Cypiripi: Exact Genotyping of CYP2D6 Using High-throughput Sequencing Data

Overview

Journal Bioinformatics

Publisher Oxford University Press

Specialty Biology

Date 2015 Jun 15

PMID 26072492

Citations 26

Authors

Ibrahim Numanagic

Salem Malikic

Victoria M Pratt

Todd C Skaar

David A Flockhart

S Cenk Sahinalp

Affiliations

Soon will be listed here.

Abstract

Motivation: CYP2D6 is highly polymorphic gene which encodes the (CYP2D6) enzyme, involved in the metabolism of 20-25% of all clinically prescribed drugs and other xenobiotics in the human body. CYP2D6 genotyping is recommended prior to treatment decisions involving one or more of the numerous drugs sensitive to CYP2D6 allelic composition. In this context, high-throughput sequencing (HTS) technologies provide a promising time-efficient and cost-effective alternative to currently used genotyping techniques. To achieve accurate interpretation of HTS data, however, one needs to overcome several obstacles such as high sequence similarity and genetic recombinations between CYP2D6 and evolutionarily related pseudogenes CYP2D7 and CYP2D8, high copy number variation among individuals and short read lengths generated by HTS technologies.

Results: In this work, we present the first algorithm to computationally infer CYP2D6 genotype at basepair resolution from HTS data. Our algorithm is able to resolve complex genotypes, including alleles that are the products of duplication, deletion and fusion events involving CYP2D6 and its evolutionarily related cousin CYP2D7. Through extensive experiments using simulated and real datasets, we show that our algorithm accurately solves this important problem with potential clinical implications.

Availability And Implementation: Cypiripi is available at http://sfu-compbio.github.io/cypiripi.

Citing Articles

Geny: a genotyping tool for allelic decomposition of killer cell immunoglobulin-like receptor genes.

Zhou Q, Ghezelji M, Hari A, Ford M, Holley C, Sahinalp S Front Immunol. 2025; 15():1494995.

PMID: 39763645 PMC: 11701374. DOI: 10.3389/fimmu.2024.1494995.

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?.

Guo H, Huang J, Wang J, Fan L, Li Y, Wu D Front Pharmacol. 2024; 15:1484512.

PMID: 39534083 PMC: 11554470. DOI: 10.3389/fphar.2024.1484512.

Characterization of complex structural variation in the gene loci using single-molecule long-read sequencing.

Turner A, Derezinski A, Gaedigk A, Berres M, Gregornik D, Brown K Front Pharmacol. 2023; 14:1195778.

PMID: 37426826 PMC: 10324673. DOI: 10.3389/fphar.2023.1195778.

An efficient genotyper and star-allele caller for pharmacogenomics.

Hari A, Zhou Q, Gonzaludo N, Harting J, Scott S, Qin X Genome Res. 2023; 33(1):61-70.

PMID: 36657977 PMC: 9977157. DOI: 10.1101/gr.277075.122.

Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.

Silgado-Guzman D, Angulo-Aguado M, Morel A, Nino-Orrego M, Ruiz-Torres D, Contreras Bravo N Front Pharmacol. 2022; 13:931531.

PMID: 35846994 PMC: 9280300. DOI: 10.3389/fphar.2022.931531.

References

Zhou S . Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009; 48(12):761-804. DOI: 10.2165/11318070-000000000-00000. View

Fang H, Liu X, Ramirez J, Choudhury N, Kubo M, Im H . Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014; 14(6):564-72. PMC: 4237721. DOI: 10.1038/tpj.2014.27. View

Kent W . BLAT--the BLAST-like alignment tool. Genome Res. 2002; 12(4):656-64. PMC: 187518. DOI: 10.1101/gr.229202. View

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

Ma Q, Lu A . Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2):437-59. DOI: 10.1124/pr.110.003533. View

Gaedigk A, Montane Jaime L, Bertino Jr J, Berard A, Pratt V, Bradfordand L . Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Front Pharmacol. 2011; 1:121. PMC: 3153001. DOI: 10.3389/fphar.2010.00121. View

Pratt V, Zehnbauer B, Amos Wilson J, Baak R, Babic N, Bettinotti M . Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn. 2010; 12(6):835-46. PMC: 2962854. DOI: 10.2353/jmoldx.2010.100090. View

Hach F, Sarrafi I, Hormozdiari F, Alkan C, Eichler E, Sahinalp S . mrsFAST-Ultra: a compact, SNP-aware mapper for high performance sequencing applications. Nucleic Acids Res. 2014; 42(Web Server issue):W494-500. PMC: 4086126. DOI: 10.1093/nar/gku370. View

Alkan C, Kidd J, Marques-Bonet T, Aksay G, Antonacci F, Hormozdiari F . Personalized copy number and segmental duplication maps using next-generation sequencing. Nat Genet. 2009; 41(10):1061-7. PMC: 2875196. DOI: 10.1038/ng.437. View

10.

Hach F, Hormozdiari F, Alkan C, Hormozdiari F, Birol I, Eichler E . mrsFAST: a cache-oblivious algorithm for short-read mapping. Nat Methods. 2010; 7(8):576-7. PMC: 3115707. DOI: 10.1038/nmeth0810-576. View

11.

Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View

12.

Zook J, Chapman B, Wang J, Mittelman D, Hofmann O, Hide W . Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol. 2014; 32(3):246-51. DOI: 10.1038/nbt.2835. View

13.

Gaedigk A, Simon S, Pearce R, Bradford L, Kennedy M, Leeder J . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2007; 83(2):234-42. DOI: 10.1038/sj.clpt.6100406. View

14.

Kramer W, Walker D, OKane D, Mrazek D, Fisher P, Dukek B . CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics. 2009; 19(10):813-22. PMC: 2862371. DOI: 10.1097/FPC.0b013e3283317b95. View

15.

Cavallari L . Tailoring drug therapy based on genotype. J Pharm Pract. 2012; 25(4):413-6. DOI: 10.1177/0897190012448311. View

16.

Kimura S, Umeno M, Skoda R, Meyer U, Gonzalez F . The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989; 45(6):889-904. PMC: 1683468. View

17.

LARKIN M, Blackshields G, Brown N, Chenna R, McGettigan P, McWilliam H . Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. DOI: 10.1093/bioinformatics/btm404. View